UK-based Vaccitech has started treating patients with influenza A vaccine MVA-NP+M1 (VTP-100) in a Phase IIb clinical trial.

Located in Antwerp, Belgium, the trial will recruit a total of 155 individuals, which will be administered with either VTP-100 or placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Designed to prevent both seasonal influenza and pandemics, VTP-100 triggers enhanced immune protection against all influenza A strains. It uses a replication-deficient pox viral vector called MVA to produce a strong immune response against Matrix 1 (M1) and Nucleoprotein (NP) influenza antigens.

Dubbed Flu 010, the Phase IIb trial is intended to evaluate VTP-100’s protective capabilities as a standalone vaccine for use in a future pandemic or pre-pandemic influenza.

Of the total participants, 134 will receive the A/Belgium/4217/2015 (H3N2) influenza virus strain.

Vaccitech expects study data to be available early next year.

The company noted that its Australian subsidiary has completed vaccination of 2,200 participants in a double-blind, randomised, placebo-controlled Flu 009 Phase IIb field trial being conducted in the country.

This trial will assess VTP-100’s additive protective efficacy against influenza-like illness when given in adjunction with existing licenced quadrivalent influenza seasonal vaccines (QIV).

Outpatients that received standard-of-care QIV earlier in the influenza season were enrolled at nine sites across Australia. The trial will investigate if VTP-100 + QIV could provide better efficacy over QIV alone.

Interim results from the trial are expected early next year. Based on the findings, the company intends to continue the study for a second season and enrol up to 6,000 participants overall in Australia.

Vaccitech CEO Tom Evans said: “We expect positive data to support the positioning of VTP-100 as a vaccine that can reduce the burden of influenza, both as a pre-pandemic intervention and as an add-on to a seasonal vaccine, especially in high-risk individuals.”